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CHARACTERIZATION OF  HUMAN 
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Procoagulant Activity Associated with the Light Chain of 
Kinin-Free High Molecular Weight Kininogen 
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(From the Allergic Diseases Section, Laboratory of Clinical Investigation, National Institute of 
Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20014) 
High molecular weight (HMW) 1 kininogen has been shown to be a  critical 
factor which functions at  the  initial  step  of the  Hageman factor-dependent 
pathways.  Thus,  plasmas  deficient  in  HMW  kininogen  have  a  markedly 
prolonged partial thromboplastin time and diminished kaolin-activatable fibri- 
nolysis  (1-4). The  Hageman factor substrates,  prekallikrein and  factor XI, 
circulate bound  to  HMW  kininogen  (5,  6)  and  are  adsorbed  to  negatively 
charged surfaces where they  interact  with  surface-bound Hageman  factor. 
HMW kininogen augments the ability of activated Hageman factor or Hageman 
factor fragments to activate prekallikrein (7-10) and factor XI  (7-11), and it 
also augments the rate of Hageman factor activation (8) and cleavage (7, 12) by 
kallikrein. Kallikrein also cleaves the HMW kininogen to liberate the vasoac- 
rive peptide bradykinin. 
We  have  previously reported that  kinin-free HMW  kininogen could  still 
function as  a  coagulation factor  (2)  and this  observation was  confirmed by 
Schiffman et  al.  (13). However,  Chan  et  al.  (14) reported  that  kallikrein 
digestion of human HMW  kininogen progressively diminished its  coagulant 
activity, while Matheson et al.  (15) assessed bovine HMW kininogen in human 
HMW kininogen-deficient plasma and found that the kinin-free protein pos- 
sessed <1% of the coagulant activity of the native molecule. In this report we 
investigate  the  structural  changes  that  occur  in  purified  human  HMW 
kininogen as a consequence of kallikrein digestion. The critical portion of the 
molecule that  is responsible for its  coagulant activity has been isolated,  as 
reported in  preliminary form  (6), and is  shown to  possess  an  antigenic de- 
terminant  that  distinguishes  HMW  kininogen  from  low  molecular weight 
(LMW) kininogen. 
* Predoctoral candidate, Department of Biochemistry, Georgetown  University, Washington, 
D.C. 
1Abbreviations  used  in  this paper:  CM,  carboxymethyl; DFP,  diisopropylfluorophosphate; 
HMW, high molecular weight; LMW, low molecular weight; PAGE, polyacrylamide gel electro- 
phoresis;  PTT, partial thromboplastin time; QAE, quaternary aminoethyl; SDS, sodium dodecyl 
sulfate. 
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Materials and Methods 
Materials.  Materials were obtained as follows: bradykinin  standard  (bradykinin  triacetate; 
Sandoz Ltd., Basel, Switzerland); hexadimethrine bromide and diisopropylfluorophosphate (DFP) 
(Aldrich Chemical Co., Inc.,  Milwaukee,  Wis.); dithiothreitol and iodoacetamide  (Calbiochem, 
San Diego, Calif.); benzamidine hydrochloride (Eastman Kodak Co., Rochester, N. Y.); quater- 
nary  aminoethyl  (QAE) Sephadex  A-50,  carboxymethyl  (CM) Sepharose,  and  Sephadex  G-200 
(Pharmacia  Fine  Chemicals,  Inc.,  Piscataway,  N.  J.);  sodium  dodecyl  sulfate  (SDS)  (Fisher 
Scientific Co.,  Fairlawn,  N. J.).  Kininogen-deficient plasma  (Williams Trait)  was provided by 
Dr. Robert Colman (University of Pennsylvania, Philadelphia,  Pa.). 
Isolation  of HMW Kininogen.  HMW  kininogen  was  isolated  from  pooled  human  plasma 
containing 0.38%  sodium citrate by a  modification of the method of Habal et al.  (16).  4 liters of 
plasma was directly applied to an 18.5  x  30-cm column of QAE-Sephadex A-50 equilibrated in 10 
mM Tris-C1, pH 8.0,  which contained 0.15  M NaC1, 0.1  mM DFP, and 20 mM benzamidine. The 
column  was  washed  with  10  liters  of this  same  Tris  buffer  containing  0.2  M  NaCI.  HMW 
kininogen  was  then  eluted  with  0.45  M  NaCI  and  fractions  were  assayed  for their  ability to 
correct the partial thromboplastin  time of HMW kininogen-deficient plasma.  Solid ammonium 
sulfate was added to 50% saturation,  and the suspension was stirred for 30 rain, then centrifuged 
for 90 min at 1,200 g. The precipitate was collected and rediseolved in -1 liter of 30 mM sodium 
acetate buffer,  pH 5.9,  containing 0.1  mM DFP and 20 mM benzamidine, and the solution was 
adjusted  to a  conductivity of 30  mS with  NaCI.  The sample was then  applied to a  5  x  20-cm 
column of CM-Sepharose equilibrated with the same buffer. HMW kininogen was eluted with a 
linear salt gradient which contained 0.6 M NaC1 in the limiting buffer. The fractions containing 
coagulant activity  were pooled,  dialyzed  against 0.1% ammonium bicarbonate containing 0.i mM 
DFP, and lyophilized.  Final purification  utilized  gel filtration  through a 5 × 100-cm column of 
Sephadex G-200 equilibrated  with 0.2 M  ammonium  bicarbonate containing 0.1 mM  DFP. 10-ml 
samples were applied, 10-ml fractions  were collected,  and the flow was 40 ml/h. Fractions were 
concentrated by lyophilization  and redissolved in 0.003  M  phosphate-buffer containing 0.15  M 
NaCI, pH 7.4. 
Purified HMW  kininogen was assessed by reduced SDS polyacrylamide  gel electrophoresis 
(SDS-PAGE)  and revealed a single  major band of 120,000 daltons (Fig. 3, first  gel).  In some 
preparations,  trace  amounts of  cleavage products were observed which were subsequently shown 
to be analogous to kallikrein digestion products of HMW  kininogen.  The HMW  kininogen 
contained no detectable Hageman factor,  prekallikrein,  factor  XI, or the a-globulin inhibitors 
CiINH, a2 macroglobulin, alantitrypsin,  a~antichymotrypsin, antithrombin Ill,  or inter-a-tryp- 
sin inhibitor. 
Reduction and Alkylation  of  HMW-Kininogen.  For reduction,  samples were made 0.05  M  in 
dithiothreitol  and incubated for 1 h at 37°C. The samples were then alkylated with 0.12 M 
iodoacetamide  and further incubated for  30 min at room temperature. 
Preparation  of  Plasma Kallikrein.  Prekallikrein was isolated  by  the  procedure of  Mandle and 
Kaplan (17).  SDS gel electrophoresis  of  reduced prekallikrein yielded two bands of  88,000 and 
85,000 daltons, respectively, as previously reported  (17) and the preparation  contained  no 
detectable Hageman factor  or factor  XI. Active kallikrein  was obtained by incubating 100/~g of 
prekallikrein with 2 /~g of Hageman  factor fragments  (18)  overnight  at 4°C. Conversion to 
kaUikrein was assessed  after  reduction and SDS-PAGE which yielded  the  characteristic  kallikrein 
heavy chain (52,000 daltens) and light chains (36,000 and 33,000  daltous) (17).  The resulting 
kallikrein  (100  ~g/ml) was then serially  diluted,  and 200 ~l ofeach dilution  was incubated with 
200 ~I HMW  kininogen (1 mg/ml) for 1 h at 37°C. Analysis of the cleaved HMW  kininogen 
samples for  bradykinin generation and by reduced SDS-PAGE  indicated the optimal concentra- 
tion  of  kallikrein  necessary in order to  obtain maximal cleavage of  HMW  kininogen in 1 h. 
Preparation of Antibody Specific for HMWoKininogen.  Antibody  to  HMW  kininogen  was 
produced in a goat by intramuscular injection of 1.0 mg HMW kininogen emulsified in complete 
Freund's adjuvant.  The goat was boosted intradermally 3 wk later with 0.5 mg HMW kininogen 
emulsified  in  incomplete  Freund's  adjuvant.  The  animal  was  bled  aRer  a  further  3  wk.  By 
immunoelectrophoresis (Fig. 1) this antiserum reacted with both the HMW and LMW kininogens 
found  in  normal  plasma,  and  a  reaction  of partial  identity  was  seen.  No precipitin  line was 
obtained when the antiserum  was reacted with the kininogen-deficient plasma  (Williams trait 490  CHARACTERIZATION  OF  HIGH  MOLECULAR  WEIGHT  KININOGEN 
FIG. i.  Immunoelectrophoresis  of normal plasma reacted against antibody to human 
kininogens (upper trough) and reacted against antibody rendered monospecific for  HMW 
kininogen (lower  trough).  A  line  of  partial  identity  between HMW  and LMW  kininogens 
is  seen. 
plasma). Adsorption of  this  antibody with Fitzgerald trait  plasma, which contains only LMW 
kininogen  (4) resulted in an antibody  which was  specific  for the unique  HMW  kininogen 
antigenic  determinants. The precipitin  arc  seen  with  this  antiserum in  the  lower trough (Fig.  i) 
corresponds to the minor precipitin  arc seen with the use of  the anti-kininogen serum in the 
upper trough. This is consistent  with previous estimates that HMW  kininogen is ~20% of  the 
total  plasma kininogen (2, 19). 
Coagulation Assay.  The partial  thromboplastin  time (PTT)  ~  was measured by the method of 
Proctor and Rapaport (20)  as  modified by Colman et  al. (2)  using  congenitally  deficient  plasmas. 
Gel Analysis.  SDS gel electrophoresis  was performed either  in cylindrical  gels  or in a slab 
apparatus (Bio-Rad Laboratories,  Richmond, Calif.)  by  the  procedure of  King and Laemmli (21). 
For reduction,  samples were made 10% in 2-mercaptoethanol  (by volume) and were boiled  for  2 
rain  in 1% SDS before  application  to  gels. 
Urea  disc  gel electrophoresis  was  performed  by the  method  of Reisfeld and  Small  (22). 
Samples were made 7  M  in  urea  and  incubated for  15  min at  37°C  before  the  gels  were loaded. 
Immunoelectrophoresis.  Immunoelectrophoresis  was performed on microscope  slides  in 1% 
agarose containing Veronal buffer,  pH 8.6,  0.06  ~, and 0.01  M  EDTA  (23). 
Bradykinin  Determination.  Bradykinin was assayed  by  bioassay with  the  isolated  guinea pig 
ileum (18). 
Results 
HMW  kininogen  was  incubated  with  1.0%  plasma  kaUikrein  by  weight  at 
37°C  for  time  intervals  of  1,  2,  and  9  h.  Samples  were  removed  and  then 
subjected to SDS-PAGE.  As seen in the nonreduced gels  (Fig.  2),  the starting 
material  had  a  major  band  at  120,000  daltons  and  a  second  band  that  was 
diminished by -15,000 daltons. Upon digestion with kallikrein for 1 h, virtually 
all  of the  material  was  found  at  105,000  daltons;  a  minor  band  was  seen  at 
100,000 daltons.  The generation of bradykinin  paralleled  the formation of this 
105,000-dalton kininogen.  Prolonged digestion for up to 9 h  revealed two major 
bands  at  105,000  and  100,000  daltons,  respectively,  as  well  as  evidence  of 
further  cleavage  to  yield  a  minor  band  at  90,000  daltons.  Identical  samples 
were also reduced and subjected to SDS gel electrophoresis.  The starting HMW 
kininogen had a major band at 120,000 daltons and minor bands at 115,000 and 
110,000,  as well  as a  band at  85,000-90,000  daltons.  Digestion with  kallikrein 
resulted in loss of each of these bands and formation of heavy chains of 56,000- 
66,000  daltons,  as  shown  in  the  gels  in  Fig.  3,  and  a  light  chain  of 37,000 R.  E.  THOMPSON,  R.  MANDLE~  JR.,  AND  A.  P.  KAPLAN  491 
Fro. 2.  Left,  SDS-PAGE  of  25 ~g HMW  kininogen alone followed by HMW  kininogen 
after digestion with 0.1%  kallikrein for 1, 2, and 9 h. Right, SDS-PAGE  of reduced 
samples  containing  25 pg HMW  kininogen alone, followed by HMW  kininogen after 
digestion  with 0.1% kallikrein  for  1,  2, and 9 h. 
daltons.  The light chain stained faintly and is best visualized in the final gel. 
Thus, in contrast to native HMW kininogen,  the kinin-free protein appeared to 
consist of multiple chains that were linked by disulfide bonds. A time course of 
digestion of a  second preparation  of HMW kininogen using 1.0%  kallikrein  by 
weight was next performed and samples were taken at intervals of up to 1 h. 
The  samples  were reduced  and  assessed by SDS-PAGE.  As shown  in  Fig.  3, 
there  was  progressive  cleavage  of the  starting  material  (120,000  daltons)  to 492  CHARACTERIZATION  OF  HIGH  MOLECULAR  WEIGHT  KININOGEN 
FIG.  3.  SDS-PAGE of reduced samples after incubation of 500 ~g HMW kininogen with 5 
/~g kallikrein at 37°C.  30  /~g of protein was  applied to the gels.  The starting material is 
shown at the left followed by samples taken after digestion for 1, 5,  10, 20, 30, and 40 rain. 
Two heavy-chain bands at 66,000 and 56,000 daltons are seen, as well as a light-chain band 
at 37,000 daltons. 
yield heavy chains at 66,000 and 56,000 daltons,  and a  light chain at 37,000 
daltons.  A  small  fraction of the  starting  HMW  kininogen preparation was 
already cleaved, as indicated by the double-banded heavy chain; however, the 
major protein present was clearly a single chain. The 66,000: plus 37,000-dalton 
bands total  103,000 daltons, thus approximating the molecular weight of the 
kinin-free protein; the 56,000-dalton  band may represent further cleavage of 
the HMW kininogen heavy chain. 
Experiments  were  next  performed to  determine the  effect of kallikrein 
digestion  and  disulfide bond  cleavage on the  ability of HMW  kininogen to 
correct the PTT of HMW kininogen-deficient plasma. Equivalent amounts of 
HMW kininogen or reduced and alkylated HMW kininogen were each incubated 
with 1% kallikrein by weight for 1 h  at 37°C. The samples were then serially 
diluted and assayed for clotting activity. As seen in Fig.  4,  neither digestion 
with kallikrein nor prior disulfide bond cleavage, nor a combination of the two 
procedures appeared to have any effect upon the clotting activity. Furthermore, 
reduction of disulfide bonds after kallikrein digestion did not alter the coagulant 
activity. 
We therefore proceeded to purify the portion of the HMW kininogen molecule 
that was responsible for its coagulant activity. 1 mg of HMW kininogen was 
digested with 2% kallikrein for 1 h  at 37°C. The cleavage products were then 
subjected to gel filtration through Sephadex G-200 equilibrated in 6 M guani- 
dine-HC1 in order to dissociate any noncovalently linked fragments. All of the 
clotting activity eluted with the major protein peak shortly behind the void 
volume of the column representing the kinin-free HMW kininogen. The only 
other peak of absorbance was located at approximately one gel bed volume of R.  E.  THOMPSON,  R.  MANDLE,  JR.,  AND  A.  P.  KAPLAN 
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FIG. 4.  Assessment of the partial thromboplastin time of HMW  kininogen before  and 
after  cleavage with kallikrein.  Identical  samples of HMW  kininogen were also  reduced 
and alkylated (R/A) and assayed before and after  digestion with kallikrein. (©),  control 
HMW  kininogen; (A),  HMW  kininogen + kallikrein;  (Q), R/A HMW  kininogen; (m),  R/A 
HMW  kininogen + kallikrein. 
the column. The initial  protein  peak was then reduced and alkylated with 0.05 
M  dithiothreitol  and 0.12 M  iodoacetamide, respectively,  and reapplied to the 
same Sephadex column. As seen in Fig. 5, two absorption peaks at 220 nm 
were obtained and all the clotting  activity  was associated with the second 
peak. SDS-PAGE analysis  of  column fractions  (shown above) revealed that the 
first  peak contained the HMW  kininogen heavy chain while the second peak 
contained the HMW  kininogen light  chain (Fig.  5). When the same fractions 
were subjected  to disc  gel electrophoresis  in 7 M  urea (Fig.  6), two light  chain 
bands were resolved.  When a replicate  sample of  gel 6 was sliced  and eluted, 
and the eluates  were assayed for  their  ability  to  correct  the coagulation  defect  of 
HMW-kininogen deficient  plasma, both  light  chain bands were shown to  possess 
coagulant  activity. The  denser  band  had  about three times the  activity 
of the minor band.  When  the heavy- and light-chain peaks were dialyzed, 
concentrated, and assessed by immunoelectrophoresis  with monospecific anti- 
body to HMW  kininogen (lower  trough; Fig. 1), a precipitin  arc was obtained 
with the light  chain, while the antiserum did not react  with the heavy chain. 
Discussion 
Purified  human  HMW  kininogen  is  a  single  chain  molecule  of  120,000 
daltons as assessed by SDS gel electrophoresis. LMW kininogen shares anti- 
genic determinants with HMW kininogen (24), and antibody to purified LMW 
kininogen has been used to prepare an immunoadsorbant that will bind both 
HMW kininogen and LMW kininogen (2,  19). Yet LMW kininogen possesses 
no known coagulant activity. It is therefore of particular interest to determine 494  CHARACTERIZATION  OF  HIGH  MOLECULAR WEIGHT KININOGEN 
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FzG.  5.  Sephadex O-200 gel filtration of reduced kinin-free HMW kininogen. The absorb- 
ance  at  220  nm is  shown  in  addition  to the  ability of portions  to correct  the  partial 
thromboplastin  time of HMW kininogen-deficient plasma. Above (inset) is shown the SDS- 
PAGE pattern obtained  after electrophoresis of 100 /~1 of tubes 60, 65, 70, and 75 (heavy 
chain), followed by electrophoresis of 100 ~1 of a 10-fold concentration of tubes 80, 85, and 
90 (light chain). 
the structural features of HMW kininogen that  are required for its coagulant 
activity and to compare them to LMW kininogen. 
Detailed  analysis  of bovine  HMW  kininogen  has  revealed  two  molecular 
forms:  one  a  single  chain  molecule,  whereas  the  other  possessed  two  chains 
that were linked by disulfide bonds (25). Since the bradykinin moiety was not 
at either end of the single-chain HMW kininogen, two peptide bond cleavages 
were  required  to  liberate  it.  However,  both  forms  of HMW  kininogen  were 
found to possess full kinin-generating capacity. It was therefore proposed that 
the  second  form  might  represent  a  kininogen  which  has  been  cleaved  at  a 
single position within a  disulfide bond. Digestion of the bovine HMW kininogen 
not  only  yields  bradykinin  but  also  liberates  a  fragment  of  14,000  daltons 
which is designated fragment 1.2 (15, 25). Subsequent cleavage of fragment 1.2 
by prolonged digestion with kallikrein yields fragment 1-a  glycopeptide (26- 
28)-and  fragment 2-a  histidine-rich peptide  (25).  When  human  HMW kini- 
nogen was  isolated rapidly,  in the presence of proteolytic inhibitors,  >90%  of 
the  isolated  product was  a  single-chain  molecule.  It therefore appears  likely R.  E.  THOMPSON,  R.  MANDLE,  JR.,  AND  A.  P.  KAPLAN  495 
FIG.  6.  Urea  disc  gel  electrophoresis  of samples  taken  from  the  Sephadex  Go200 gel 
filtration of reduced kinin-free HMW kininogen (Fig. 5).  100/~1 of tubes 60, 65,  70, and 75 
followed by  100  ~1  of a  20-fold  concentration  of tubes  80,  85,  and  90  were  applied.  A 
replicate gel of sample 6 (second 5-om right) was sliced, each slice was eluted with 0.2 ml 
PBS,  and the eluates were assayed for their ability to correct the partial thromboplastin 
time of HMW kininogen-deficient plasma.  The peaks  of coagulant activity seen at slices 
36-38 and 40-44 correspond to the two bands seen in the gel. 
that  two-chain  forms  of human  HMW kininogen  reported  by others  (29),  as 
well as one of the forms of bovine HMW kininogen,  have been cleaved during 
the process of purification.  Our findings are in general agreement with those of 
Nagasawa  and  Nakayasu  (30)  who  purified  human  HMW kininogen  in  the 
presence  of both  benzamidine  and  DFP,  and  isolated  a  single-chain  form. 
Although a  reduction in molecular weight of kallikrein-digested human HMW 
kininogen  is observed (Fig.  2),  we have not isolated the peptides,  if any, that 
are released. 
Evidence  that  human  HMW  kininogen  is  heterogeneous,  however,  does 
exist.  Reduced SDS gel electrophoresis of the starting  material  reveals two or 
three bands differing by 5,000-10,000 daltons,  each of which can be cleaved by 
plasma kallikrein.  In addition,  the unreduced kinin-free  kininogen  is seen as 
two bands (Fig.  2) and, upon reduction, the heavy chain is seen as two or more 
bands  (Figs.  2,  3).  The  sum of these two major forms of heavy chain  (Fig.  3) 
totals  122,000,  which exceeds the  size  of the kinin-free  material.  It therefore 
appears unlikely that  each is a  separate chain of kinin-free  HMW kininogen. 
Furthermore,  the  isolated  heavy  chain  appears  homogeneous  by  antigenic 
analysis,  and  the  sum  of the  molecular  weight  of the heavy chain  and  light 
chain  approximates  that  of kinin-free  HMW kininogen.  Thus,  kallikrein-di- 
gested,  kinin-free  HMW kininogen  appears  to consist of a  single heavy-chain 
disulfide linked to a  single  light  chain.  The heterogeneity of the heavy chain 496  CHARACTERIZATION  OF  HIGH  MOLECULAR  WEIGHT  KININOGEN 
bands observed may reflect the size heterogeneity of the starting material and/ 
or represent further proteolysis by plasma kallikrein. Clearly, in Fig. 2 we see 
gradual conversion to the 100,000 dalton molecule of a portion of the kinin-free 
HMW  kininogen seen at  105,000  daltons.  Although the  light  chain  appears 
homogeneous by  size  it,  too,  demonstrates heterogeneity when  assessed  by 
urea disc gel electrophoresis (Fig.  6). 
As  shown in  Fig.  4,  digestion of HMW kininogen with plasma  kallikrein 
does  not  affect  its  ability  to  function  as  a  coagulation  factor  and  neither 
reduction and alkylation of HMW kininogen before or after interaction with 
kallikrein,  nor  exposure to  6  M  guanidine  hydrochloride affects its  clotting 
activity. An apparent loss of ~15,000 daltons accompanies kallikrein cleavage. 
Thus,  neither bradykinin nor any other liberated peptide is required for the 
expression of this function. Our data therefore do not agree with reports that 
kallikrein digestion of human (14) or bovine (15) HMW kininogen destroys its 
coagulant  activity  and  confirms  the  earlier  observation  that  the  kinin-free 
protein  retains  full  activity  (2).  It  is  possible  that  species  incompatibility 
accounts for the fact that digested bovine HMW kininogen will not clot human 
HMW kininogen-deficient plasma.  Consistent with this suggestion is a  recent 
report  indicating  that  the  clotting  activity  of the  undigested  bovine  HMW 
kininogen may represent only a fraction of that obtained with equal quantities 
of the human protein (31). Nevertheless, the coagulant activity of the starting 
material  was  retained  upon  digestion with  urinary kallikrein,  and  a  chain 
containing  bovine  fragment  1.2  attached  to  light  chain  was  shown  to  be 
responsible for the activity (31). Perhaps the human counterpart of fragment 
1.2 is not cleaved from the light chain by plasma kallikrein. 
It is also possible that one or more peptides could adhere to the human kinin- 
free protein or to its isolated light chain by noncovalent interaction and thereby 
contribute to  the coagulant activity seen.  However, when the human kinin- 
free protein is reduced, alkylated, and exposed to 6 M guanidine, the isolated 
light  chain contains all  of the coagulant activity.  Furthermore, the isolated 
light chain (Fig.  5) does not differ in size from that observed when kallikrein- 
digested HMW kininogen is reduced and subjected to SDS gel electrophoresis 
(Fig. 2). The two forms of light chain observed upon urea disc gel electrophoresis 
may reflect charge heterogeneity (Fig.  6).  However,  we  also considered the 
possibility that one band might represent a small peptide bound to light chain 
that resists dissociation in urea and guanidine and that might be important for 
the  observed  coagulant  activity.  Since  both  forms of light  chain  possessed 
coagulant activity, if binding of a small peptide were responsible for the hetero- 
geneity,  it  would  not  be  critical  for  functional  activity.  We  therefore  con- 
clude  that  the  light  chain  of  human  kinin-free  HMW  kininogen  is  the 
coagulant part of the molecule. The light chain also contains a unique antigenic 
determinant that  distinguishes  HMW kininogen from LMW kininogen.  This 
finding is in agreement with observations that the amino acid compositions of 
the  heavy chains  of bovine  HMW  and  LMW  kininogens  are  identical  (32). 
Thus,  kininogens appear to share heavy chains.  It is possible that Williams 
trait plasma  (2),  which is  deficient in  both  forms of kininogen,  has  a  defect 
involving the  heavy chain,  while  Fitzgerald trait  plasma  (4),  which has  no R.  E.  THOMPSON,  R.  MANDLE,  JR.,  AND  A.  P.  KAPLAN  497 
HMW kininogen but has about one-third to one-half normal LMW kininogen, 
has a  defect in the HMW kininogen light chain.  Further studies are now in 
progress  to  evaluate  the  structural  features  required  for  binding  of HMW 
kininogen to surfaces and to bind prekallikrein and factor XI. 
Summary 
Human high molecular weight (HMW) kininogen has been isolated and was 
found to be  a  single chain protein of ----120,000 daltons.  Upon digestion with 
plasma kallikrein bradykinin is generated, and SDS gel electrophoresis of the 
kinin-free protein reveals an apparent loss in size of 15,000 daltons. The kinin- 
free kininogen retains full activity as a  coagulation factor and consists of two 
chains: a  heavy chain of ----66,000 daltons disulfide-linked to  a  light chain of 
37,000 daltons. The heavy chain of HMW kininogen shares antigenic determi- 
nants with  LMW kininogen and  possesses  no  detectable coagulant activity. 
The isolated light chain is shown to be responsible for the coagulant activity of 
HMW  kininogen  and  contains  a  unique  antigenic  determinant that  distin- 
guishes HMW kininogen from low molecular weight kininogen. 
Received for publication 13 September 1977. 
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